NEW TECHNOLOGIES TO IMPROVE THE MICRONUTRIENT STATUS OF TARGETED POPULATIONS

IFST SPRING CONFERENCE, UNIVERSITY OF BIRMINGHAM, UK
APRIL 4TH 2019

Dr Rob Winwood CSci FIFST, Vice-Chair of the Council for Responsible Nutrition UK and Manager of Nutrition Science and Advocacy for DSM Nutritional Products, EMEA region
- Introduction
- Activity Trackers
- How to use technology to increase the global supply of marine omega 3 fatty acids when the world fish oil stocks are declining - the Veramaris project.
- Determination of Macular Pigment Optical Density (MPOD) by optometrists in the high street and remedial supplementation of lutein/zeaxanthin - the Macuwell™ project
- How Personalised nutrition is becoming a reality in the market place
ACTIVITY TRACKERS
Activity trackers are now in widespread use to measure personal fitness, well-being and sleep patterns.

Activity trackers are now used in clinical trials. In 2012, Van Remortel et al. carried out a systematic review on how activity trackers can be used to provide useful biometric measurements in patients suffering chronic disease (Int J Behav Nutr Phy Activ 2012; 9(84)).

More recently it has been shown they can be successfully used to assess the fitness status of adolescent Australians (Ridgers ND et al., 2018, JMIR Nhealth Uhealth: 6(4): e86).

Kooiman TJM et al, used them to determine the effect of type 2 diabetes on mobility (2018, Computers, Informatics, Nursing; 36(7): 340-349.).

It therefore makes perfect sense to use biomarkers derived from activity trackers to measure directly benefits of micronutrients which are thought to improve mobility and fitness (e.g. Vitamin D, glucosamine, marine omega 3 fatty acids).
THE VERAMARIS PROJECT

HOW TO SUSTAINABLY MEET THE INCREASING GLOBAL DEMAND FOR MARINE OMEGA 3’S WHEN FISH STOCKS ARE IN DECLINE
Low omega-3 levels are widespread – particularly in the Western World.

Coastal regions of countries and populations that traditionally rely on hunting, fishing and gathering for sustenance tend to have moderate to adequate omega-3 levels.

VERAMARIS AIM TO PROVIDE SUPPLY SECURITY FOR EPA AND DHA OMEGA-3

• DSM and Evonik are both long term partners of the salmon feed industry.
• Decades of experience in algal technology and large scale fermentation.
• Commitment to the aquaculture industry: 200 mio USD investment in the new Veramaris algal oil fermentation and production facility
• Commercial capacity (from 2019) onwards: 15 % EPA + DHA annual supply requirement of the salmon industry.

• Specialist for the cultivation of marine organisms including algae
• Biotechnology capabilities in development and operations
• Specialist in developing industrial biotechnology processes
• Know-how in operating competitively large scale manufacturing sites for fermentative amino acids.
Currently, limited wild fish stocks are used on an industrial scale to produce fish oil and fishmeal.

16,000,000 tons wild fish

~17% of global wild catch is consumed for the production of fish oil and fishmeal

Source: IFFO, FAO
LOOMING EPA+DHA SUPPLY GAP: THE TRADITIONAL SUPPLY OF OMEGA-3 FROM FISH OIL WILL LIMIT THE GROWTH OF THE AQUACULTURE INDUSTRY

- Market supply demand for omega-3

1. Supply: Approximately 900k tonnes per year
   • limited supply of fish oil as source of omega-3 fatty acids

2. Demand: Increasing demand for EPA+DHA
   • Aquaculture industry growth and EPA+DHA biological requirement
   • Consumer demand for omega-3’s and healthy nutrition

3. Supply-demand gap
   • EPA+DHA supply gap will emerge in the near future

➢ Meeting the demand for omega-3 fatty acids by utilizing new and sustainable sources of EPA + DHA in the future.
POTENTIAL DECREASE IN VALUE OF SALMON FILET: THE OMEGA-3 LEVELS IN FARMED SALMON HALVED DURING THE LAST DECADE

Levels of EPA + DHA in farmed Scottish Atlantic salmon between 2006 and 2015


If nothing was done the level of the beneficial omega-3 can only really go down.

Prof Douglas Tocher
Stirling University
OUR NATURAL MARINE ALGAL OIL IS A SUSTAINABLE ALTERNATIVE SOLUTION FOR EPA AND DHA SUPPLY

Veramaris breakthrough - shortening the natural food chain
VERAMARIS ALGAL OIL WILL ENABLE THE FISHFEED INDUSTRY TO KEEP UP WITH THE INCREASING DEMAND FOR EPA AND DHA

Omega-3 innovation from natural marine algae

Rich in both EPA and DHA for complete nutrition

EPA and DHA content greater than 50%

Free from Ocean-born contaminants such as dioxins & PCB’s

Non-GMO

No Ethoxyquin

Liquid product

High purity

Broad use in animal nutrition from aquaculture to pet food

Image: marine microalgae with omega-3 fatty acid droplets
THE MACUWELL™ PROJECT
THE EYE IS A COMPLEX ORGAN.

THE PRESENCE OF SOME SPECIFIC MICRONUTRIENTS ARE IMPORTANT FOR GOOD EYE HEALTH

- Lutein
- Zeaxanthin
- Astaxanthin
- Beta-Carotine
- DHA
- Vitamin A
- Vitamin E
- Vitamin C
- Others (e.g., Resveratrol, Anthocyanine)
- Others (e.g., Resveratrol, Anthocyanine)

NUTRITION IS THE KEY FOR GOOD EYE HEALTH

A balanced diet that ensures vitamins, polyunsaturated fatty acids, anti-oxidants and minerals in the recommended amounts is essential for the function and long-term health of the eye.

The nutrients support the function and health of the eye:-
• Protect against oxidative damage
• Maintain the function of the optic nerves
• Reduce the risk of night blindness

These nutrients can only reach the eye through the diet, the human body can not produce them.
Fortified foods or dietary supplements are an important additional source to supplement the diet.
THE MACULA IS RICH IN TWO CAROTINOIDS—LUTEIN UND ZEAXANTHIN.

Only two carotenoids from the food chain are found in the macula, about 50 of which we ingest via the diet and of which about 20 are in the blood.

The human body can not produce lutein and zeaxanthin itself. Zeaxanthin is an isomer of lutein that has the same primary functions as lutein in the macula, but has a different concentration distribution.

On average, the diet results in a 5:1 intake of lutein to zeaxanthin. For this reason many human studies were done with the same concentration ratio, with lutein being 10 mg and zeaxanthin 2 mg per day.

Photos Courtesy of www.shutterstock.com
The retinal carotenoid content is low. The highest concentration is in the macula. The zeaxanthin concentrates in the centre. Lutein is more widely distributed.

Data provided by Dr. Richard Bone
Against the recommended daily intake of 10mg + 2mg Lutein the average levels in Europe for both are actually 0.5-4 mg/day. (Kemin Discovery' Report, 2016)

An intake of both of 6 mg per day is required to reduce the risk of age related macular degeneration - the leading cause of sight loss in mature adults. (Seddon et. al. JAMA 1994;272:14120)

SUPPLEMENTATION WITH LUTEIN AND ZEAXANTHIN CAN RAPIDLY INCREASE MPOD

Starting at an MPOD <0.4

10mg lutein & 2mg zeaxanthin supplementation increases MPOD.

The values increase with the duration of supplementation.

Adapted from Stringham & Hammond 2008 Optom Vis Sci 85:82
In 2016, AMD cases among people over the age of 50 in the EU were estimated at 17.1 million. Of these, 2.53 million, or 18.9% of all AMD cases are severe cases or cases in the last stage.

The total cost of these severe cases and cases in the final stage is €102.64 billion a year. These costs include direct health costs as well as indirect costs.
This project involves both optometrists and industry where equipment is supplied to measure the macular pigment optical density (MPOD) of patients. MPOD is measured by the optometrist using the MPS II retinal scanner (manufactured by Cambridge based Elektron Eye Technology) that uses heterochromatic flicker photometry (HFP) technology.

If a patient’s retina has lower level of pigment density, then more blue light gets through to the retina. As a result, they are particularly susceptible to blue light damaging the light-sensitive cells.

Low MPOD levels reduce visual acuity, and in the long term, leads to the increased risk of sight loss due to age-related macular degeneration.

However, a simple, targeted intervention of a supplement containing the relevant carotenoid pigments: lutein and zeaxanthin, can be directly supplied to the patient by the optometrist and the resulting increase in MPOD measured until it is at an acceptable level.
HOW PERSONALISED NUTRITION IS BECOMING A REALITY IN THE MARKET PLACE

Recent advances in wearable health-related technologies, non-invasive medical biomarker measurement and genotype determination, mean that the holistic benefits offered by micronutrient interventions can now be properly determined.
Bringing personalized nutrition to you.

There are three main components of the Mixfit system:

1. **Mixfit Device**
   The first at-home nutrient delivery appliance that uses predictive modeling to dispense a great-tasting personalized drink formulated to deliver nutrients your body may be lacking.

2. **Mixfit App**
   The technology platform powered by MINA (Mixfit Intelligent Nutrition Assistant), it integrates key data points from your lifestyle, diet, and activity into our proprietary algorithm to formulate your supplement drink in real time.

3. **Nutritional Subscription**
   Never worry about running out — Mixfit offers a simple monthly subscription customized to you. Here’s how: the Mixfit device monitors your levels and triggers a shipment to make worrying about refills a thing of the past.

Source: [www.gomixfit.com](http://www.gomixfit.com)

Source: [www.nutritioninsight.com](http://www.nutritioninsight.com)
Mixfit claims to be the first nutrients delivery appliance that uses an algorithm (Mixfit Intelligent Nutrition Assistant or MINA) on a smart phone App (Android and Apple) to determine your nutritional requirements.

The resultant requirements are then programmed into the Appliance device to produce a ready-to-consume drink.

The Mixfit Device is preloaded with all the necessary core nutrients (23 essential micronutrients) in 8 cannisters. In addition, single use speciality pods can be purchased to achieve a particular nutritional goal e.g. recovery after a workout or provide more energy.

The device is designed to be used twice a day but can be programmed for alternative frequencies. The device will recognise the profiles of each individual in a household.
COMING SOON!
PERSONALIZED VITAMINS
The future of personalized nutrition is almost here. Join the waitlist for updates on the next release.
Personalized Formulations Produced in Innovative Forms

Replace Multiple Pills - with - Flavorful Gel and Puree Combinations of Same Actives

Patented Software and Hardware Technology Makes it Possible

Source: www.panaceutics.com
**PANACEUTICS**

lab assays → metabolomics → genomics → personal profile → precision formula → small batch automation → “n of 1” → optimized efficacy → integrated therapies → higher adherence

Source: www.panaceutics.com
- Whilst government-led nutrition policies throughout Europe have meant that diseases directly related to extreme micronutrient deficiency are largely a thing of the past, it is increasingly being recognised that the optimum intake of many micronutrients is not being achieved, increasing the risk and early onset of many non-communicable diseases (NCDs).

- The “one size fits all approach” of nutrient intake survey has major limitations. An individual’s micronutrient needs will depend on their genotype.

- Hence, it is important to be able to have “easy to perform” analysis of specific nutrients in blood and other tissues to determine the “in-vivo” status. This provides a strong argument for the concept of personalised nutrition.
Thank you!

BRIGHT SCIENCE. BRIGHTER LIVING.™

This information is based on DSM’s current knowledge. Although DSM has used diligent care to ensure that the information provided herein is accurate and up to date, DSM makes no representation or warranty of the accuracy, reliability, or completeness of the information. This information only contains scientific and technical information for business to business use. Use of this information shall be at your discretion and risk. Nothing herein relieves you from carrying out your own suitability determinations and tests. We do not assume any liability in connection with your product and its use. This information does not relieve you of your obligation to comply with all applicable laws and regulations and to observe all third party rights. Country or region-specific information should also be considered when labelling or advertising to final consumers.

This information does not constitute or provide scientific or medical advice, diagnosis, or treatment and is distributed without warranty of any kind, either expressly or implied. In no event shall DSM be liable for any damages arising from the reader’s reliance upon, or use of, these materials. The reader shall be solely responsible for any interpretation or use of the material contained herein. The content of this document is subject to change without further notice. Please contact your local DSM representative for more details. All trademarks listed in this brochure are either registered trademarks or trademarks of DSM in The Netherlands and/or other countries.